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Context. Based on the clinical care pathway of delirium in palliative care (PC), a published analytic framework (AF)
formulated research questions in key domains and recommended a scoping review to identify evidence gaps.
Objectives. To produce a literature map for key domains of the published AF: screening, prognosis and diagnosis,
management, and the health-related outcomes.
Methods. A standard scoping review framework was used by an interdisciplinary study team of nurse- and physician-
delirium researchers, an information specialist, and review methodologists to conduct the review. Knowledge user
engagement provided context in refining 19 AF questions. A peer-reviewed search strategy identified citations in Medline,
PsycINFO, Embase, and CINAHL databases between 1980 and 2018. Two reviewers independently screened records for
inclusion using explicit study eligibility criteria for the population, design, delirium diagnosis, and investigational intent.
Results. Of 104 studies reporting empirical data and meeting eligibility criteria, most were conducted in patients with
cancer (73.1%) and in inpatient PC units (52%). The most frequent study design was a one or more group, nonrandomized
trial or cohort (67.3%). Evidence gaps were identified: delirium risk prediction; comparative effectiveness and harms of
prevention, variability in delirium management across PC settings, advanced directive and substitute decision-maker input,
and transition of care location; and estimating delirium reversibility. Future rigorous primary studies are required to address
these gaps and preliminary concerns regarding the quality of extant literature.Presented in part at the 15th World Congress of the Euro-
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Delirium is a complex neurocognitive and behav-
ioral manifestation of an underlying medical abnor-
mality. Its frequent occurrence is therefore not
unexpected in the context of patients with advanced
life-threatening illness in palliative care (PC) settings.
Although the terms PC and hospice care are often
used interchangeably, PC is considered applicable any-
where in a person’s life-threatening illness trajectory,
whereas hospice care has a more traditional associa-
tion with the terminal phase of end-of-life care.1
Both specialists and generalists deliver PC across a va-
riety of settings: inpatient PC units in acute care set-
tings and stand-alone inpatient hospices; hospital PC
consult teams; and community PC services.1 Although
delirium is acknowledged as a frequent clinical prob-
lem in the context of PC,2 its poor recognition and
documentation in clinical practice is a substantive
concern.3,4 Across all health care settings, delirium is
associated with high levels of mortality and morbidity,
and poorer outcomes in general5,6; it is thus a major
contributor to health care costs.7
Standardized clinical criteria, such as those of the
International Classification of Diseases, 10th and
recently released 11th edition (ICD-10 and ICD-11),
and the Diagnostic Statistical Manual of Mental Disor-
ders, fifth edition (DSM-5), exist to aid clinicians in
diagnosing delirium.8e10 The Confusion Assessment
Method (CAM) is a briefly administered assessment
tool that is widely used to screen for delirium.11
Although it was validated in relation to the earlier
DSM-III-R criteria,12 it broadly operationalizes the cur-
rent DSM-5 delirium criteria.13 The DSM-5 delirium
features include the following: a disturbance of atten-
tion and awareness; short onset (hours to days) and
fluctuation over the course of the day; an additional
cognitive disturbance, such as disorientation, memory,
or language deficits, or perceptual abnormalities; the
disturbances are not better explained by an evolving
or existing dementia, or that they occur in a coma;
and there is clinical evidence through history, exami-
nation or investigations that the disturbance is related
to another general medical condition, substance
intoxication (e.g., a medication) or withdrawal, or
multiple etiologic factors.13 On the basis of the typeof psychomotor disturbance observed, delirium is clas-
sified as no motor subtype (normal psychomotor activ-
ity), hypoactive or hyperactive, or a mixed subtype
with both hypoactive and hyperactive features.14,15
The hypoactive subtype is common in PC settings
and is the most prone to go undetected.16 Misdiag-
nosis of delirium most commonly occurs as dementia
and depression.17e19 Regular screening for delirium
in PC settings has been advocated,20,21 particularly in
view of its characteristic fluctuations, the frequency
of the hypoactive subtype, and the risk of misdiag-
nosis, but there has been very limited evaluation of
the effectiveness of screening in this context.22
Although advanced age, preexisting or evolving de-
mentia, and frailty may confer a baseline vulnerability
or risk toward delirium in older persons in general,2
delirium occurring in the PC context is particularly
precipitated by one or more acute medical events,
such as organ failure, infection, and medication or
metabolic effects.23 Although baseline and precipitant
risk factors for delirium have been identified in other
care settings, there has been relatively limited evalua-
tion of these in PC settings. Furthermore, findings
from studies that evaluate either delirium risk or ther-
apeutic interventions in settings such as postoperative
or critical care may have limited generalizability to PC
settings. Delirium generates high levels of distress for
patients, their families, and their professional care-
givers in PC settings by impeding potentially precious
communication and generating behavioral distur-
bances.24 The standard PC approach to delirium man-
agement involves symptomatic management and
treatment of reversible precipitating factors (if consis-
tent with the goals of care) in addition to patient and
family support.22,23,25 Symptomatic management may
involve varying degrees of nonpharmacological and
pharmacological interventions.22,26
Most patients in PC settings experience an irrevers-
ible delirium in the last hours or days of life.27 Part or
full reversal of delirium may occur before the terminal
phase but depends on the presence of modifiable etio-
logic factors, their investigation, and treatment. The
patient’s goals of care are typically more focused on
comfort in many PC settings, particularly in hospice
care. This may limit the investigation and treatment
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use of antipsychotic and other sedating medications
to symptomatically treat delirium. If the goals of care
are unclear and clinical uncertainty exists regarding
the reversibility of an episode of delirium, there is a
potential risk of adopting the extremes of either un-
due fatalism (missing potentially reversible delirium
precipitants and premature use of deep pharmacolog-
ical sedation to control the symptoms of delirium) or,
alternatively, taking an overly medicalized (inappro-
priately burdensome and nonecost-effective interven-
tion) approach to delirium management.23
The association of delirium with older age, demen-
tia and comorbidity burden,2,28 and the projected
population increase in the proportion of elderly per-
son29 together signal a pressing need for knowledge
synthesis to guide all practitioners in palliative and
end-of-life care to conduct effective, evidence-based
interventions at all points along the clinical care
pathway of delirium. Recognizing this need, our
group organized an international interdisciplinary
research planning meeting with a broad spectrum of
leading delirium researchers and knowledge-users in
2012 as part of an overarching program of research,
entitled Studies to UNderstand Delirium In Palliative
Care Settings (SUNDIPS).30 We identified key areas
of potential uncertainty, controversy, or clinical equi-
poise in the clinical care pathway of delirium in PC:
the benefit/burden ratio for therapeutic decisions;
the outcomes and impact of delirium; the goals of
care; the use of deep pharmacological sedation to con-
trol the symptoms of delirium; cost-effectiveness is-
sues; patient-reported outcomes, experiential impact
of delirium, and its treatment on family and care-
givers; and limited access to certain therapeutic inter-
ventions and the potential need to transition to a new
place of care, such as home to hospice or hospice to
acute care. We subsequently constructed and pub-
lished an analytic framework (AF) with pivotal
research questions, based on the delirium care
pathway in PC.31
As a preliminary step, a comprehensive map of the
scope and nature of the knowledge in the scientific
literature and its gaps is a prerequisite to proceeding
with systematic reviews and further clinical research
studies.31 We conducted a scoping review of delirium
in PC settings with specific aims: 1) to map the litera-
ture for the key domains and pivotal questions in the
clinical care pathway of delirium in PC settings, as pre-
viously identified in our AF: screening, prognosis, and
diagnosis; management (including pharmacological
and nonpharmacological therapeutic interventions)
in the context of the goals of care; and outcomes
and impact, including clinical, experiential (patient,
family, and professional caregivers), and economic;
2) to identify the knowledge gaps and researchpriorities regarding delirium in PC settings, thus
providing the potential to refine the existing research
questions in our AF, and determine where systematic
reviews are feasible and warranted before planning
future clinical research studies; and 3) to consolidate
our integrated knowledge user, consultative and
collaborative process, as initiated in our SUNDIPS
meeting, so as to address the specific contextual
decision-making issues regarding delirium in PC and
establish research priorities.Methods
Study Team Composition
The core study team consisted of two PC physicians
based in an inpatient care setting, a critical care physi-
cian, two postdoctoral PC nursing delirium re-
searchers, a critical care pharmacoepidemiologist, an
information specialist, a systematic review methodolo-
gist, an epidemiologist, and two research assistants.
Collaborative author input was received from a psychi-
atrist who conducted many delirium studies in a hos-
pice setting and PC physicians from across a variety
of settings, including a community consult service, a
hospital consult service, and a university academic
department.
Scoping Review Framework
A scoping review has been defined as ‘‘a form of
knowledge synthesis that addresses an exploratory
research question aimed at mapping key concepts,
types of evidence, and gaps in research related to a
defined area or field by systematically searching, se-
lecting, and synthesizing existing knowledge.’’32
Scoping reviews thus represent a novel approach to
mapping the landscape of published literature.
Following previous recommendations regarding
scoping review methodology,32,33 we adopted a stan-
dard six-phase framework approach to the conduct
of the review: 1) developing a rationale and identi-
fying the research questions; 2) identifying relevant
studies; 3) study selection; 4) charting the data; 5)
collating, summarizing, and reporting the results;
and 6) collaborative consultation, which partly pre-
ceded but was also an integral part of Phase 1 and
Phase 5 of this framework.
Developing a Rationale and Identifying the Research
Questions
The background and rationale for this scoping re-
view have been described in relation to the inaugural
SUNDIPS meeting.30,31 Many of the knowledge-users,
methods experts, and independent researchers who
attended this meeting collaborated on many of its
related publications.21,27,31,34e36 Although a broader
664 Vol. 57 No. 3 March 2019Lawlor et al.consultative meeting is not a formal requirement in
scoping reviews,33 we considered the initial and sus-
tained engagement of knowledge-users (administra-
tors, senior nursing personnel, and policy
developers) as an important aspect of the review. We
therefore scheduled an initial two-hour meeting of
knowledge-users and core study team members to re-
view the research questions from the AF. Through
this meeting and both subsequent consultation and
iterative input, the 18 initially identified AF questions
were refined and a question in relation to transition of
care was added. An updated version of the AF is de-
picted in Figure 1, and the refined research questions
now totaling 19 are outlined in Table 1. We did not
publish or register the protocol because of the
absence of such formal arrangements for scoping re-
views but signaled the basis of the scoping review in
our published AF paper.31
Consistent with standard recommendations that the
primary research question of a scoping review be
broad, we asked the question: What is the scope and
nature of the scientific literature addressing the assess-
ment, management, outcomes, and impact of
delirium in PC settings? This broad questionFig. 1. Analytic framework based on clinical pathway of deliriencompasses the specific AF research questions, as
initially identified in the SUNDIPS meeting and
further refined through subsequent consultation.
Identifying Relevant Studies
A search strategy was developed by an experienced
information specialist (L. S.) and externally peer re-
viewed by another information specialist. The search
was conducted across Medline (via Ovid), Embase
(via Ovid), CINAHL (via EBSCOhost), and PsycINFO
(via Ovid) databases. Pilot screening of a sample of
retrieved records was used to further refine the search
concept and strategy and help finalize key data extrac-
tion items. The search strategy included a combina-
tion of various terms in relation to ‘‘palliative care’’
and ‘‘delirium.’’ (Appendix 1, Supplementary
Table 1). The strategy was modified as appropriate
in accordance with the specific database searched. Sec-
ondary searching of the included studies was also used
to identify and map studies in relation to the pivotal
areas in the AF. The literature search was initially
limited to the time period of 1980 to July 2, 2015;
further updated searches were conducted on
December 31, 2016, and May 16, 2018. The rationaleum with key domains and related research questions (Q).
Table 1
Research Domains and Questions Related to Analytic Framework in Figure 1
Epidemiological burden of delirium
1. What are the incidence and prevalence rates of delirium in the various palliative care settings (acute care, inpatient hospice and hospital
care, and community palliative services)?
Delirium prediction and prevention
2. What are the baseline and precipitating risk factors for onset of delirium?
3. What is the performance of the various delirium risk prediction models under current standards of care and how do they compare with
each other?
4. Does the model have transportability or external validity?
5. What are the comparative effectiveness and harms of the various delirium-preventative management strategies (including but not limited
to management guided by delirium risk prediction) among themselves or between them and a no delirium-preventative management
option?
Screening for delirium in PC settings
6. What is the test performance of the various delirium screening tests (e.g., cognitive active screening, informal caregiver observational
passive screening, etc.) and how do they compare with each other?
7. What are the comparative effectiveness and harms of the various delirium screening tests/strategies among themselves or between them
and a no screening option (e.g., cognitive active screening of all patients vs. cognitive active screening triaged by nurse/informal caregiver
observational passive screening for important delirium-associated outcomes)?
Diagnosis and classification of delirium
8. What is the diagnostic performance of the various validated delirium diagnostic and classification tools (in current use) and how do they
compare with each other?
9. What are the comparative effectiveness and harms of the various validated delirium diagnostic and classification tools/strategies (in
current use) among themselves or between them and a no diagnostic testing option or no classification option, respectively?
Management of delirium
10. What is the extent of variability in management of delirium across the various care settings (acute care, inpatient hospice and hospital
care, and community palliative services)?
11. Is the variability in management of delirium across the various care settings (acute care, inpatient hospice and hospital care, and
community palliative services) associated with important differences in outcomes of benefits and harms?
12. What are the comparative effectiveness and harms of delirium management strategies that incorporate advanced directives and/or
substitute decision-maker input versus those that do not?
13. What are the comparative effectiveness and harms of the various pharmacologic symptom-directed interventions among themselves,
against nonpharmacologic therapies or a no therapy option?
14. What are the comparative effectiveness and harms of the various nonpharmacologic symptom-directed interventions among themselves,
against pharmacologic therapies or a no therapy option?
15. For patients in community settings (private home, nursing home, long-term care facility) who develop delirium in the context of
predominantly palliative goals of care, what is the comparative effectiveness (e.g., higher probability of reversal of delirium; quality of life
gain; reduction of family caregiver burden) and harms (undue invasive procedures, break in continuity of care, burdensome transition;
potential separation from family) of transfer to hospital care settings (emergency or inpatient care) or inpatient hospice care for
subsequent management versus continued care in their community settings? What patient or environmental factors might explain any
observed heterogeneity in outcomes across studies?
Prediction of response to management and treatment of delirium
16. In patients with established delirium, what are the risk factors that predict its nonreversibility or its complete or partial reversibility and
sustainability of response?
17. What is the performance of the various risk prediction models that predict complete or partial reversibility of delirium under current
standards of care and how do they compare with each other?
18. Does the model have transportability or external validity?
19. What are the comparative effectiveness and harms of patient management guided by models predicting delirium reversibility among
themselves or between them and a no delirium prediction-based management option?
PC ¼ palliative care.
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diagnostic criteria for delirium before 1980.
Study Selection
The titles and abstracts of those studies identified in
the literature search were uploaded into DistillerSR,37
a software program designed to support the conduct
of systematic reviews. Explicit a priori eligibility
criteria (Table 2) were applied at Level 1 (title and ab-
stract) and Level 2 (full text) screening. The principal
inclusion criterion was for the study (including system-
atic reviews) to address one or more of the 19 ques-
tions in the AF. Furthermore, from a feasibility
perspective, we reserved the option of modifying the
scoping review and limiting it to a subset of questionsif either the volume of retrieved records or included
studies became unmanageable.
In addition to including relevant studies that were
clearly documented as having been conducted in palli-
ative settings and involving participants with a clearly
defined principal palliative indicator diagnosis, we
also included relevant studies whose study populations
had cancer or adult immune deficiency syndrome
(AIDS) as a progressive life-threatening illness and
were unequivocally eligible for PC referral but had
study assessments conducted by oncology, psychiatry,
psycho-oncology, or a designated supportive care ser-
vice. We excluded publications such as editorials, com-
mentaries, narrative reviews, and letters that did not
report primary empirical data. Studies were excluded
Table 2
Eligibility Criteria for Delirium Scoping Review
1. Inclusion criteria: a record was included if it provided an answer to at least one of the 19 questions (see Table 1) in the analytic framework
(see Fig. 1) and meets none of the exclusion criteria.
2. Exclusion criteria: a record was excluded if it met one or more of the criteria (aei); reviewers selected a single best response.
a) Availability: insufficient information to ascertain relevance beyond title (neither abstract nor full text are available)
b) Language: abstract and/or full text of record is in a language other than English
c) Sample size: less than 20 participants
d) Population: not adult (exclusively or as an analytic subgroup) or does not meet the contextual criterion of patients in palliative care
settings (admitted to an inpatient palliative care or hospice unit; followed by a hospital consult palliative care team; having cancer or
AIDS as a progressive life-threatening illness and unequivocally eligible for palliative care referral but assessed by an oncology, psychiatry,
psycho-oncology, or supportive care service; or under the care of a community hospice or palliative care program)
e) Diagnosis of delirium: is not clearly defined according to standard criteria such as one or more of the following: Diagnostic and
Statistical Manual (DSM) of Mental Disorders criteria for delirium, International Classification of Diseases (ICD) diagnostic criteria, a
diagnostic cutoff score on a validated assessment (diagnostic or screening) tool such as the Confusion Assessment Method (CAM), or
standard psychiatric assessment
f) Design: it is not a systematic review, randomized controlled trial, or analytic observational study (cohort, case-cohort, nested case-control,
case-control, or time series)
g) Investigational intent (primary or secondary): does not aim to empirically investigate any of the following:
 incidence or prevalence estimates of delirium or its level of reversal (complete, partial, or nonreversal)
 risk factors for delirium onset or its reversal (complete, partial, or nonreversal)
 accuracy, performance, effectiveness or harms of medical tests for screening, diagnosis, or classification of delirium
 development, performance, validation, effectiveness or harms of risk prediction models for delirium onset or its reversal (complete,
partial, or nonreversal)
 comparative effectiveness or harms of delirium-preventative management strategies
 variability in management of delirium across palliative care settings
 comparative effectiveness or harms of delirium management or treatment, transfer to hospital care settings (emergency or inpatient
care), or inpatient hospice care for subsequent management
 cost-effectiveness of delirium screening, diagnosis, classification, prognosis, or management/treatment
h) Insufficient information: investigational intent, study design, population, or sample size remains unclear due to insufficient information
in full-text or abstract-only records
i) Other reason(s): as documented by reviewers
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cording to standard criteria such as DSM or ICD diag-
nostic criteria, or a diagnostic cutoff score on a
validated assessment (diagnostic or screening) tool
such as the CAM, or standard psychiatric assessment.
The scoping methodology supported an inclusive
approach, which involved the inclusion of conference
abstracts and systematic reviews, based on their
meeting eligibility criteria and their potential to
address at least one of the 19 AF questions.
Full texts of included studies were examined to
confirm inclusion, extract relevant data, and map
them to specific research questions. In the absence
of a full-text publication, an abstract-only article was
included if it otherwise met the eligibility criteria.
Dual screening at Levels 1 and 2 was conducted inde-
pendently by two senior researchers (P. G. L. and S. H.
B.), and all conflicting selections were discussed and
resolved, if necessary, through the input of a third
reviewer (M. T. A.). The single best reason for exclu-
sion at Level 2 was also recorded. The data extraction
process was undertaken by a single reviewer (P. G. L.)
with a two-reviewer (P. G. L. and S. H. B.) consensus
reserved for unclear records. As a quality check to
verify the accuracy of data extraction, a random 10%
of the data were independently verified by a third
reviewer (N. A. R.).Charting the Data
Data extraction included the following items:
study design, country of origin, study population,
sample size, delirium diagnostic criteria used or vali-
dated tool used for diagnosis, and key outcome do-
mains. Study records were tagged by the research
question(s) that they addressed. In keeping with
the standards for scoping reviews, included studies
were not formally appraised for risk of bias.33,38 We
adopted an inclusive approach to comparative effec-
tiveness and harms evaluation: in addition to thera-
peutic interventions, we also included screening
and diagnostic and prognostic tool evaluations if
they reported some comparative effectiveness or
harms outcomes.Collating, Summarizing, and Reporting the Results
Cognizant of the potential overlap between some
primary studies and included systematic reviews,
relevant findings were reported separately or
discretely (e.g., using the term ‘‘multiple’’ in relation
to systematic review characteristics) where possible
to avoid exaggerating the available evidence in rela-
tion to our research questions. We used the broad
qualitative characteristics and the numerical distri-
bution of mapped evidence addressing each of the
Vol. 57 No. 3 March 2019 667Scoping Review of Delirium in Palliative Carea priori research questions to formulate our recom-
mendations for future research: a subsequent sys-
tematic review, a survey of patient experience or
experience of those who care for patients at risk of
or in delirium in a PC setting, or a primary experi-
mental/observational study to fill the knowledge
gaps identified.
Toward the end of the project, once the data were
summarized, the knowledge-users were again con-
sulted and their opinions noted in relation to future
research priorities from among the research ques-
tions, the identified knowledge gaps, and the potential
for knowledge synthesis, as generated through the
scoping review. The main outcome of our scoping re-
view was to answer the broad primary research ques-
tion and thus advance the SUNDIPS program of
research by setting the foundation for future studies.Fig. 2. PRISMA flow diagram fResults
Study Screening and Inclusion
The literature search, including updates, identified
6800 citation records. The flow of information in iden-
tifying, screening, and selecting studies is summarized
in the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA)39 flow diagram in
Figure 2. Screening at title and abstract level identified
390 citation records as eligible to proceed to full-text
review level. Of the 287 references reviewed and
excluded at full-text review level, the three most
frequent single reasons for exclusion were the investi-
gational intent of the study (n ¼ 90), the study design
(n ¼ 63), and the lack of valid diagnostic criteria used
for delirium diagnosis (n ¼ 56), together accounting
for 209 (73%) of the single reasons for exclusion. A to-
tal of 104 studies therefore met the eligibility criteriaor delirium scoping review.
668 Vol. 57 No. 3 March 2019Lawlor et al.for final inclusion.40e143 These included a published
PhD thesis50 and also a prospective study with 19 pa-
tients106 that, despite the arbitrary eligibility cutoff of
20 for sample size, was deemed by consensus to
warrant inclusion because of the very few studies
that prospectively evaluated terminal delirium. Eleven
of the included studies were conference abstracts
with no available full text but were included
because their abstracts met the review’s eligibility
criteria.40,58,74,79,89,99,104,114e116,143
General Study Characteristics
The general study characteristics of the included
studies are summarized individually in Appendix 2,
Supplementary Table 2, and an aggregate summary
of their characteristics with citations is presented in
Table 3. Thirty-seven studies (35.6%) originated
from the U.S.; 14 (13.5%) from Japan; 10 (9.6%)
from Canada; 6 (5.8%) from two or more countries;
6 (5.8%) from Australia; 5 (4.8%) from U.K.; 4
(3.8%) from each of Ireland, Spain, and Portugal; 2
(1.9%) from each of the Netherlands, Germany, Italy,
and Taiwan; and 1 (1%) from each of Hong Kong,
South Korea, Belgium, Norway, Turkey, and Mexico.
Seventy-six (73.1%) study samples were individually
comprisedmostly ($79%)of subjects with a cancer diag-
nosis. Eight (7.7%) studies had sample subjects with a
heterogeneous mix of life-threatening diagnoses. In 3
(2.9%) studies,54,75,141 all or$90% of the sample had a
diagnosis of AIDS.One (1%) studywas conducted exclu-
sively inpatientswithhepatic failure139 and1(1%)exclu-
sively inpatientswithdementia.121 In 12 (11.5%) studies,
the palliative indicator diagnosis was unclear or not re-
ported. The baseline dementia status was unclear or un-
reported in 55 (52.9%) of the included studies. Patients
with dementia were excluded in 15 (14.4%) studies, and
33 (31.7%) studies included or reported a mix of pa-
tients with and without dementia. In 1 (1%) study,121
all patients had dementia. Three studies reported a sub-
group analysis on the basis of dementia status.47,56,111
One included study (1%) reported the baseline Parkin-
son’s disease status of the study sample.94
Forty-eight (46.2%) studies were conducted exclu-
sively in single-center inpatient PC units. The other
PC-specific settings of study samples consisted of a
mix across hospital and community settings. Seven-
teen (16.3%) studies were conducted through a psy-
chiatry service in an eligible population for study
inclusion in our review. A further 15 (14.4%) studies
were conducted in hospitalized oncology patients
who met our population eligibility criteria, but PC
service involvement was not reported, and similarly,
1 (1%) study of patients with cancer attending a
cancer center emergency department was also
included.Of the included studies, 60 (57.7%) were uncon-
trolled, nonrandomized trials or single-group cohort
studies, 10 (9.6%) involved two or multiple groups
in a nonrandomized trial or cohort study (compara-
tive studies of two or more interventions, tests, risk fac-
tors, or other exposures). Forty-two (40.4%) of the
included studies had either a prospective cohort
design or a prospective cohort component, and a
further 12 (11.5%) were reported as secondary ana-
lyses of prospectively collected data; the remainder
(n ¼ 15) of the cohort studies were retrospective.
The second most frequent design was cross-sectional,
occurring in 18 (17.3%) studies. There were both 5
(4.8%) formal systematic reviews and randomized
controlled trials among the included studies. Based
on reviewer consensus, two additional reviews were
included124,131: both involved systematic literature
searches and addressed some of the AF questions
but lacked a quality appraisal of their included studies,
and by definition were not formal systematic reviews.
Apart from these reviews, the remaining 97 included
primary studies were conducted in a total of 25,690
subjects. Most (79.8%, n ¼ 83) of the study samples
had a mix of adult age groups and were not age
selected. Similarly, most (71.2%, n ¼ 74) of the study
samples comprised a heterogeneous mix of male
and female subjects. Age and sex status were either un-
clear or unreported in 15 (14.4%) and 25 (24%)
studies, respectively.
The diagnostic criteria and/or validated assessment
tools used to make the diagnosis of delirium are sum-
marized in Appendix 3 and Supplementary
Table 3.8,9,12,55,67,82,144e156 The most common criteria
used among the included studies were those of the
DSM: the DSM-IV146 or DSM-IV-TR147 was used in 45
(43.3%) studies, and the DSM-III-R,145 in 9 (8.7%)
studies. Of validated tools, the CAM,12 Delirium Rat-
ing Scale (DRS) or its revised form (DRS-98-R),148,149
and MDAS55 were used in 32 (30.8%), 17 (16.3%),
and 27 (26%) studies, respectively. A classification of
delirium based on psychomotor status was reported
in 36 (35%) studies; one of these also reported a syn-
dromal and subsyndromal classification.127
Studies of Epidemiological Burden, Prediction, and
Prevention of Delirium
Studies investigating the epidemiological burden
(prevalence or incidence), prediction, and prevention
of delirium are summarized in Table 4 in relation to
related questions (Q1eQ5) from the AF. A total of
48 (46.2%) and 31 (29.8%) studies investigated preva-
lence and incidence, respectively. Thirty-eight studies
(36.5%) investigated risk factors for the onset of
delirium; these included 9 (8.7%) studies that re-
ported some form of risk prediction model. There
Table 3
Aggregate Summary of Study Characteristics of Included Studies (N ¼ 104)
Study Characteristics Studies N ¼ 104 (%)
Geographic origin
U.S.45e57,60,63e66,69e71,73e75,94,104,106,120e122,128,133,134,136,139,141,142 37 (35.6)
Japan42,97,107,108,112e115,117,118,130,137,138,140 14 (13.5)
Canada76e83,100,101 10 (9.6)
Multiple countries62,91,93,95,109,110 6 (5.8)
Australia40,41,92,105,127,132 6 (5.8)
U.K.44,59,89,126,135 5 (4.8)
Other43,58,61,67,68,72,84e88,90,96,98,99,102,103,111,116,119,123e125,129,131,143 26 (25)
Palliative indicator diagnosisa
Cancer in all or $90% 40,42,43,45e53,55e57,60,61,63e66,68e73,77e81,83,85e88,90e94,96e108,111e118,122,125,127,129e133,135e138,140 74 (71.2)
Heterogeneous mix of life-threatening illnesses41,44,62,76,119,120,128,134 8 (7.7)
AIDS54,75,141 3 (2.9)
AIDS or cancer (systematic reviews, each included reference #54)59,95,124 3 (2.9)
Hepatic failure139 1 (1)
Dementia121 1 (1)
Unclear or unreported58,67,74,82,84,89,109,110,123,126,142,143 12 (11.5)
Care setting or service
Single inpatient palliative care unit (PCU) 48 (46.2)
Hospital based44,58,67,69,74,88,92,96,98e101,103,108,111,112,114,115,117,118,125,136,143 23 (22.1)
Hospice based57,72,78,79,84,102,107,109,110,121,123,126e129,135 16 (15.4)
Cancer center based65,66,85e87,93,94,133 8 (7.7)
Institutional base unclear141 1 (1)
Inpatient PCU combined with either one or more other inpatient PCU or a non-inpatient PC setting 6 (5.8)
Inpatient PCUs40,41,43,61,77 5 (4.8)
Inpatient PCU with community PC setting120 1 (1)
Other specific PC settings 11 (10.6)
Hospital PC consult service63,71,89,113,116,138,142 7 (6.7)
Community PC settings64,76,134 3 (2.9)
Hospital PC outpatient setting104 1 (1)
Multiple PC settings in formal systematic reviews and systematic literature reviews62,90,91,95,124,131 6 (5.8)
Psychiatry service referrals in eligible population42,45e48,53e56,59,60,75,97,106,122,130,139 17 (16.3)
Hospitalized oncology patients49e52,68,73,80e83,105,119,132,137,140 15 (14.4)
Cancer center emergency department70 1 (1)
Study design
Formal systematic review59,62,90,91,95 5 (4.8)
Randomized controlled trial41,54,57,94,103 5 (4.8)
Uncontrolled nonrandomized trial or cohort with one or more groups 70 (67.3)
Prospective40,56,61,67e69,72,73,75,77,78,81e88,93,96e98,100,102,105e107,112,116e118,121,123,125,126,128e130,140,143 41 (39.4)
Mixed prospective cohort and cross-sectional parts135 1 (1)
Secondary analysis of prospective data45e53,66,80,134 12 (11.5)
Retrospective42,58,63,64,71,74,104,108,115,119,122,133,137,138,141 15 (14.4)
Unclear or unreported111 1 (1)
Cross-sectional study43,55,60,65,70,76,79,92,99,101,109,113,114,120,127,132,136,139 18 (17.3)
Case-control study110,142 2 (1.9)
Uncontrolled before-after study44,89 2 (1.9)
Nonformal systematic review study with systematic literature reviewb,124,131 2 (1.9)
Demographics of study sample subjects
Age
Age mixed/not age selected41,42,45e49,53e64,66e73,75e88,91e94,96e103,105e113,117e120,122,123,125,127e130,132e138,141e143 83 (79.8)
Age $ 6550e52,74,140 5 (4.8)
Age < 59139 1 (1)
Unclear or unreported40,43,44,65,89,90,95,104,114e116,121,124,126,131 15 (14.4)
Sex
Mixed/not sex selected41,42,45,46,48e57,59,61e64,66,68e73,76e78,81,83e88,91e94,96e101,103,105e113,117,118,120,122,123,
125e130,132,133,135e138,140
74 (71.2)
Male only selected75,134,141,142 4 (3.8)
Female only selected60 1 (1)
Unclear or reported40,43,44,47,58,65,67,74,79,80,82,89,90,95,102,104,114e116,119,121,124,131,139,143 25 (24)
aIn two additional studies,102,136 cancer was the principal palliative indicator diagnosis in 87.2% and 79% of subjects, respectively.
bBoth of these reviews involved systematic literature searches and addressed some of the AF questions but lacked a quality appraisal of their included studies and
by definition were not formal systematic reviews.
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effectiveness/harms of delirium prevention strate-
gies,57,77 one involved hydration as a preventive
intervention,57 and no study examined delirium-
preventative management strategies guided by risk
prediction.Studies of Screening, Diagnosis, and Classification of
Delirium
Studies investigating the screening, diagnosis, and clas-
sification of delirium are summarized in Table 5 in rela-
tion to related questions (Q6eQ9) from the AF. A total
of 18 (17.3%) studies investigated delirium screening;
Table 4
Studies That Addressed the Epidemiological Burden, Prediction, and Prevention of Delirium
Research Domains and Related Questions (Q)a Study Reference Number Studies N ¼ 104 (%)
Epidemiological burden of delirium
Q1 Prevalence investigated 42,44,50,52,58,60,63e65,70e72,75,76,78e83,
87e93,96,98e100,104e107,111e114,116,
120,126,135,136,139e141,143
48 (46.2)
Incidence investigated 50,52,58,60,66e68,73,75,77e82,88,91,98,100,
105,106,114e116,119,125e127,134,137,142
31 (29.8)
Prediction and prevention
Q2 Investigates risk factor(s)
for onset of delirium
(risk association study)
40,48,50,52,53,58,61,66,68,73,75,81,83,84,88,
98e100,104e108,114,115,118,119,122,125,
126,130,134,135,137,139e142
38 (36.5)
Q3 Involved development of
delirium risk prediction
model (or score)
73,81,83,105,114,119,134,141,142 9 (8.7)
Q4 Investigates transportability
or external validity of risk
prediction model
0 (0)
Q5 Investigates effectiveness and/
or harms of delirium-preventative
management strategies guided by
risk prediction
0 (0)
Compares effectiveness and harms
of other delirium-preventative
management strategies with each
other or routine care?
57,77 2 (1.9)
aDomains and questions (Q1eQ5) from the analytic framework as presented in Table 1 and Figure 1.
670 Vol. 57 No. 3 March 2019Lawlor et al.these included 7 (6.7%) and 5 (4.8%) studies that investi-
gated the diagnostic performance of a screening test
against a reference standard, and the diagnostic perfor-
mance of two or more screening tests against a referenceTable
Studies That Addressed Screening, Diag
Research Domains and Related Questions (Q)a
Screening
Q6 Investigates screening to detect subsyndromal and/
or full syndromal delirium
44
Investigates the diagnostic performance of a
delirium screening test versus a reference
standard
62
Investigates the comparative diagnostic
performance of delirium screening tests (Test A
vs. reference standard; Test B vs same reference
standard)
62
Q7 Investigates comparative effectiveness and/or
harms of screening tests among themselves or
between them and routine patient care
44
Diagnosis and classification
Q8 Investigates the establishment of delirium diagnosis 43
Investigates the diagnostic performance of a
delirium diagnostic test versus a reference
standard
43
Investigates the comparative diagnostic
performance of delirium diagnostic tests (Test A
vs. reference standard; Test B vs. same reference
standard)
82
Q9 Investigates comparative effectiveness and/or
harms of diagnostic tests among themselves or
between them and routine patient care
89
Q8 Investigates diagnostic performance of one or more
psychomotor classification test(s) of delirium
84
Q9 Investigates comparative effectiveness/harms of
one or more psychomotor classification test(s) of
delirium
aDomains and questions (Q6eQ9) from the analytic framework as presented in Tstandard, respectively. Nine (8.7%) studies reported the
comparative effectiveness or harms of screening tests.
A total of 9 (8.7%) studies investigated the diagnosis
of delirium; these included 6 (5.8%) and 2 (1.9%)5
nosis, and Classification of Delirium
Study Reference Numbers Studies N ¼ 104 (%)
,62,64,67,72,78,80,82,89,90,121,126e129,132,136,139 18 (17.3)
,64,67,78,90,129,136 7 (6.7)
,80,82,132,139 5 (4.8)
,62,72,80,89,121,126e128 9 (8.7)
,55,82,89,90,101,110,113,123 9 (8.7)
,55,90,101,110,123 6 (5.8)
,110 2 (1.9)
,101,113 3 (2.9)
,109,131 3 (2.9)
0 (0)
able 1 and Figure 1.
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nostic test against a reference standard, and the test
performance of two or more diagnostic tests against
a reference standard, respectively. Three (2.9%)
studies reported on the comparative effectiveness or
harms of diagnostic tests.
A total of 3 (2.9%) studies investigated the psycho-
motor classification of delirium; these included 2
(1.9%) and 1 (1%) studies that investigated the diag-
nostic performance of a psychomotor classification
test against a reference standard, and the diagnostic
performance of two or more psychomotor classifica-
tion tests against a reference standard, respectively.
None of these studies reported on the comparative
effectiveness or harms of psychomotor classification
tests.Studies of the Management of Delirium and Prediction
of Response
Studies investigating the management of delirium
and the prediction of response to management are
summarized in Table 6 in relation to related ques-
tions (Q10eQ19) from the AF. A total of 24
(23.1%) studies investigated the comparative effec-
tiveness or harms of one or more pharmacological
management approach (Q13), whereas 2 (1.9%)
studies, including a systematic review, investigated
the comparative effectiveness or harms of nonphar-
macological management approaches (Q14). A total
of 13 (12.5%) studies investigated risk factors for
the prediction of response (reversibility) to the
management of delirium (Q16); these included 4
(3.8%) studies of predictive models for reversibility
(Q17). None of the included studies investigated
variability in delirium management across PC set-
tings (Q10, Q11), delirium management strategies
incorporating advanced directives (Q12), or the
impact of transition of care setting for delirium
management (Q15).Table
Studies That Addressed the Management o
Research Domains and Related Questions (Q)a
Management approach
Q13 Investigates comparative effectiveness and/
or harms of one or more pharmacological
management approaches to delirium
41,45e48,53,54,
Q14 Investigates comparative effectiveness and/or
harms of one or more nonpharmacological
management approaches to delirium
131,138
Prediction of response to management
Q16 Prediction of response (reversibility)
to management of delirium
49,51,53,56,68,9
Q17 Investigates model development for
predictors of delirium reversibility
98,100,102,111
aDomains and questions (Q10eQ19) from the analytic framework as presented in T
questions: Q10e12, Q15, Q18, and Q19.Reported Comparative Effectiveness or Harms
Outcomes
A total of 37 (35.9%) of the included studies re-
ported comparative effectiveness or harms outcomes;
three of these studies involved the use of additional
assessment tools that were not previously referenced
in the review: the Richmond Agitation-Sedation Scale
(RASS)157, the Chinese version of the DRS (DRS-Chi-
nese)158, and MinieMental State Examination159.
(Appendix 4, Supplementary Table 4). Thirteen
(12.5%) of these studies involved a direct comparison
of two or more active study interventions46e48,54,59,62,
74,80,86,94,95,103,124. Among these, there were two formal
systematic reviews, one of screening tools62,95,119, and
one of pharmacological intervention95 that overlap-
ped with a primary study;54 one systematic literature
review study of pharmacological interventions124, over-
lapping with two primary studies47,54; one study of
screening80; the remaining 10 studies involved phar-
macological comparisons with most having delirium
severity change and adverse events related to therapy
as study outcomes. A further 13 (12.5%) studies
included two formal systematic reviews, one of
screening tools62 and one of assisted hydration and
delirium severity95; a systematic literature review study
that reported on effectiveness and harms of pharma-
cological interventions and exercise131, overlapping
with one primary study in relation to exercise138; pri-
mary studies comparing one or more active study in-
terventions against placebo41,57 or no active
intervention122,138 or current standard manage-
ment,72,77,113,121,127 or reference standard in the
context of an assessment tool101. A total of 14
(13.5%) studies reported comparative effectiveness
or harms using a before and after analysis; these
included one systematic literature review study124,
overlapping with a primary study on olanzapine56;
four studies of assessment tools44,89,126,128, and the re-
maining nine studies involved pharmacological inter-
vention45,53,56,69,75,85,107,117,133. Although a wide6
f Delirium and Prediction of Response
Study Reference Numbers Studies N ¼ 104 (%)
56,57,59,69,74,75,85,86,94,95,97,103,107,117,122,124,133 24 (23.1)
2 (1.9)
8,100,102,111,118,122,124,130 13 (12.5)
4 (3.8)
able 1 and Figure 1: none of the included studies mapped onto the following
672 Vol. 57 No. 3 March 2019Lawlor et al.variety of outcomes were reported in association with
comparative effectiveness and harms analyses, neither
falls nor economic cost were among these outcomes.
Objective outcomes were most commonly reported,
for example, delirium severity measure changes and
adverse events related to treatment were reported in
21 (20.3%) and 18 (17.3%) of studies, respectively,
whereas experiential outcomes were infrequently
reported.
Evidence Gaps and Potential Opportunities for
Further Studies
Based on identified gaps, the study group’s recom-
mendations regarding future primary studies and
related outcomes, endorsed by knowledge user consul-
tation, are summarized along with systematic review
opportunities in Table 7. Among the studies investi-
gating the epidemiological burden (prevalence or
incidence), prediction of and prevention of delirium
(Q1-5 in AF), there were substantive study numbers
to address Q1-3, with most of the risk factor studies re-
porting crude, unadjusted risk association. However,
none of the studies with risk prediction models re-
ported external validation (Q4) and there were only
two studies addressing Q5, the prevention of delirium
in PC settings. Overall, these data suggest that there
are enough studies to consider systematic reviews for
Q1-3 and that further primary studies are needed forTable
Future Research Recommendations Regard
Research Strategy AF Domain/Questions (Qs)
Systematic review (SR) Epidemiological burden (Q1)
Prognosis (Q2e3)
Screening (Q6)
Diagnosis (Q8e9)
Classification (Q8)
Management (Q13e14) and reversibility (Q1
Primary studies Risk factor identification and prevention stra
(Q2e5)
Screening, diagnosis, and classification (Q6e
Management issues (Q10e19)
Outcomes needing further evaluation (relate
Q2e19 in AF)
AF ¼ analytic framework; CEH ¼ comparative effectiveness or harms; RCT ¼ ranQ4-5. Among the studies investigating delirium
screening (Q6-7), diagnosis (Q8-9), psychomotor clas-
sification (Q8 only), and management (Q13e14 and
Q16e17 only) there appears to be sufficient numbers
of studies to support the conduct of a systematic re-
view in relation to each of these questions. Remark-
ably, none of the primary studies that were included
in this scoping review addressed the questions
regarding variability of practice across different PC set-
tings (Q10e12), nor did any address the comparative
effectiveness or harms of care location transition in
relation to delirium (Q15), the external validation of
any of the predictive models for delirium reversibility
(Q18) or their comparative effectiveness or harms
(Q19), indicating the need for primary studies in rela-
tion to Q10e12, Q15 and Q18e19.Discussion
Using recommended scoping review methods, 104
published studies with empirical data were mapped
onto research domains and key questions from a pre-
specified AF. In addition to the contribution of recog-
nized delirium researchers, the generation of key
questions and their subsequent refinement and
expansion was based on the initial and ongoing
engagement of a broad spectrum of decision-makers
and knowledge-users from clinical, administrative,7
ing Delirium in Palliative Care Settings
Relevant Focus or Recommendation
 Incidence and prevalence; pooled estimates
 Predictive model and risk association studies
 Screening test performance and CEH
 Diagnostic test performance and CEH
 Sufficient studies for test performance only
6e17)  CEH; current formal SRs require updating
 Predictive model and risk association studies
tegies  Predictive models for delirium occurrence; predictive
score to determine risk; CEH of such models/scores
 RCTs of preventive strategies, particularly
nonpharmacological interventions to prevent
delirium
9)  Diagnostic performance studies of assessment tools
in these domains
 CEH studies of screening, diagnosis, and
psychomotor classification
 Variability across PC settings and related outcomes
 Advanced directives and goals of care designation
 Community studies and impact of transition of care
setting for delirium management
 Pharmacological and particularly
nonpharmacological intervention; both RCTs and
PTs
 Externally validated predictive models for
reversibility
d to  CEH in general, including assessment and
management interventions
 Experiential (patient/family/professional caregiver)
 Economic cost
domized controlled trial; PC ¼ palliative care; PT ¼ pragmatic trial.
Vol. 57 No. 3 March 2019 673Scoping Review of Delirium in Palliative Careand policy sectors in palliative and hospice care. These
collective perspectives informed commentary on core
aspects of the review: general appraisal of the litera-
ture; the strengths, challenges and limitations of the
review; methodological and other considerations
regarding future research. The emerging methodolog-
ical concerns, as identified in the scoping review,
along with related recommendations are summarized
in Table 8.
General Appraisal of the Literature
Of the 278 excluded studies at full-text-level review,
56 (19.5%) were excluded because of failure to report
clear or valid delirium diagnostic criteria, which high-
lights the importance of using standardized diagnostic
criteria in future studies. Most (73.1%) of the
included studies in the review were conducted in pa-
tients with cancer. This raises concerns for the gener-
alizability for some research findings to the broader
current and projected PC population, which will not
only include a substantive proportion of patients
with cancer but increasingly is likely to be comprised
of a heterogeneous mix of palliative indicator diagno-
ses, comorbid chronic illness and multimorbidity,
including dementia and various organ failure diagno-
ses.160,161 Moreover, dementia is one of the strongest
risk factors for delirium in the elderly, yet its baseline
status was either not reported or unclear in 52.9% of
the studies included in the review. Similarly, the base-
line Parkinson’s disease status was only documented in
one study; this is a concern, particularly in studies of
antipsychotics in delirium management and the
need to determine extrapyramidal effects due to these
medications. Of the included studies, approximately
half were conducted in inpatient PC units, whereas
only 6.7% and 2% were conducted in hospital PCTable
Additional Methodological Considera
Methodological Issue
Defining a palliative care population  Reali
some
more
altern
Delirium diagnosis  Use I
valida
 Diagn
Baseline documentation of dementia status  Docu
consi
Baseline documentation of Parkinson’s disease status  Docu
extra
Outcomes: definition; evaluation of additional outcomes  Defin
 Expe
mixed
Collaboration  Cons
PTs
 Cons
PC ¼ palliative care; ICD ¼ International Classification of Disease9,10; DSM ¼ Diag
trial; PT ¼ pragmatic trial.consult service settings and community PC settings,
respectively. The generalizability of any study findings
across these different study settings could be problem-
atic. There were few systematic reviews and random-
ized controlled trials (RCTs); the lack of RCTs may
reflect ethical, symptom burden, and attritional chal-
lenges of conducting such studies in frail PC popula-
tions.36,162 Taken together, the underrepresentation
of certain palliative indicator diagnoses in study sam-
ples, the low number of hospital consultation and
community-based PC service studies, the deficits in
baseline documentation, and the relative paucity of
RCTs and systematic reviews highlight gaps and raise
both generalizability and quality concerns in the cur-
rent literature, with the caveat that a full quality and
risk of bias appraisal is beyond the remit of a scoping
review.
Strengths, Challenges, and Limitations of the Review
This review has many strengths: a rigorous peer-
reviewed search strategy; an updated search of the
most relevant databases; engagement of knowledge-
users; interprofessional study team input with high-
level clinical and methodological expertise; refined
and expanded key questions derived from an AF
that was based on the clinical pathway of delirium in
PC; independent dual screening of records; and
conduct of the review in accordance with recommen-
ded standards. The restriction of studies selected to
those of English language is a limitation. We also
encountered many challenges in conducting the re-
view, some of which might also be acknowledged as
limitations.
One of the challenges encountered was semantic
ambiguity in relation to delirium terminology. The
literature on delirium is replete with multiple terms8
tions Regarding Future Research
Recommendation
ty is that the PC population is becoming increasingly heterogeneous;
studies (e.g., risk factor evaluation) may benefit from selecting a
homogeneous sample regarding palliative indicator diagnosis;
atively, consider stratification or subgroup analysis
CD/DSM standard criteria or standard cutoff score on a tool
ted against ICD/DSM criteria
ostic algorithm for chart diagnosis/coding in database studies
ment due to potential impact on outcomes and their evaluation;
der stratification or subgroup analysis on the basis of dementia status
ment particularly in studies of antipsychotics; potential to cause
pyramidal side effects
ition of core outcomes
riential outcomes for patients, families, and professional caregivers;
-methods approach will likely be required for some aspects
ider multicenter collaboration to facilitate recruitment for RCTs and
ider interdisciplinary and knowledge user collaboration
nostic Statistical Manual of Mental Disorders8; RCT ¼ randomized controlled
674 Vol. 57 No. 3 March 2019Lawlor et al.for delirium28, such as encephalopathy and acute
confusional state, to name just two. We addressed
this issue in part by setting clear eligibility criteria
for study inclusion: for the diagnosis of delirium,
included studies were required to have met DSM or
ICD diagnostic criteria or have used a diagnostic score
on an assessment tool that had been either directly or
indirectly validated against the DSM or ICD diagnostic
criteria. Despite this, there were many studies of he-
patic encephalopathy, for example, in which we
strongly suspect that the subjects had delirium. How-
ever, although the criteria used specifically for hepatic
encephalopathy were clearly met in these studies, they
were not directly congruent with DSM or ICD criteria.
This mismatch in taxonomy between the disciplines of
hepatology and psychiatry meant that many of the he-
patic encephalopathy studies were excluded at Level 1
or 2 screening phases.
We encountered somewhat similar issues in relation
to defining the PC population for the purposes of the
review. The World Health Organization definition of
PC is inclusive of those with ‘‘life-threatening
illness.’’163 This broad definition includes many pa-
tients who are admitted to critical care units, although
such units might not be conventionally viewed as
‘‘palliative care settings’’ per se. There has been a
huge surge in studies of delirium in critical care over
the past decade, and although this has contributed
greatly to our understanding of delirium, the focus
and intensity of medical management may differ quite
a bit between an inpatient hospice and critical care
setting. Consequently, studies of patients admitted to
critical or intensive care were excluded in our review:
the consensus was that ultimately the inclusion of crit-
ical care studies of delirium, although desirable, might
limit the generalizability of the scoping review find-
ings. We acknowledge this as a limitation that was
arguably unavoidable. We also encountered some un-
certainty regarding studies of patients with cancer or
AIDS as a progressive life-threatening illness and
were not necessarily seen by a PC service in consulta-
tion yet were unequivocally eligible for PC referral
but assessed by oncology, psychiatry, psycho-
oncology, or supportive care services; such studies
were included in our review if they otherwise met
the eligibility criteria.
Although the AF key questions encompassed many
of the pertinent decision-making questions in the clin-
ical care pathway of delirium, we acknowledge that the
review’s calibration toward addressing these clinical
and epidemiological questions with empirical data
and the consequent exclusion of gray literature and
qualitative studies could mean that important compo-
nents of care such as family education and support
may have fallen outside the scope of the review. Simi-
larly, by limiting the scope of screening and diagnosticassessment tools to the PC context, perhaps the search
did not capture studies addressing the use of delirium
assessment tools in other populations or contexts that
might have potential applicability in the PC setting.
Moreover, the outcomes reported in the included
studies were largely clinical and limited in relation to
patient, family, and professional caregiver experience.
Although we adopted a standardized approach to
capturing data in relation to knowledge user input
through the SUNDIPS meeting, funding restrictions
meant that subsequent knowledge user input was re-
corded in a less formal, standardized, and therefore
transparent manner. Furthermore, lack of a more
formal engagement of knowledge-users at the end of
the study can be viewed as a missed opportunity in
terms of knowledge translation.
Methodological and Other Considerations Regarding
Future Research
Based on absence of data, primary studies are
required in relation to many issues in the care pathway
of delirium in PC settings: external validation of
delirium risk prediction models; comparative effec-
tiveness and harms of prevention strategies and psy-
chomotor classification of delirium; variability in
delirium management and related outcomes across
the various PC settings and in relation to advanced
directive and substitute decision-maker input; the
experiential impact of transition of care location in
relation to delirium management; and external valida-
tion of predictive models in estimating delirium
reversibility. In addition to these primary study re-
quirements, other primary studies and methodolog-
ical issues warrant consideration.
Our group is currently conducting systematic re-
views of delirium in the PC context with regard to its
epidemiological burden, assessment, and reversibility.
Although systematic reviews appear feasible in relation
to some of our research questions, our preliminary
concerns, based on a broad and admittedly not an
in-depth appraisal of quality and risk of bias of the
selected extant literature, also indicate a need for
more rigorous primary studies in relation to the do-
mains or questions for which data already exist. This
is particularly relevant to the evidence base for
delirium management in PC, especially the pharmaco-
logical approach to the symptomatic management of
delirium in PC settings, for which four RCTs were
identified in the review.41,54,94,103 One of these RCTs
included a placebo arm and demonstrated better
symptom distress scores in the placebo-treated group
compared to the antipsychotic-treated (haloperidol
or risperidone) groups.41 This result has generated
vigorous debate and calls for more studies regarding
this issue.164 A recent survey of medical specialists in
Palliative Medicine highlighted the marked variability
Vol. 57 No. 3 March 2019 675Scoping Review of Delirium in Palliative Carein pharmacological management of delirious symp-
toms and the perceived need for more rigorous
studies.165 Although RCTs contribute the highest level
of evidence, depending on the intervention, prag-
matic clinical trials, despite their challenges,166 may
provide useful data regarding effectiveness, and in
the PC setting may offer a more feasible alternative.
Risk prediction models or scores for the onset and
reversibility of delirium could potentially provide key
information for optimal management decision-
making by categorizing and triaging patients into spe-
cific risk categories and accordingly tailoring patient
management.167,168 Use of this approach has the po-
tential to reduce unnecessary testing and treatment,
thus minimizing related harms and costs. Evidence
for risk prediction is ideally developed sequentially,
involving development, validation, and impact assess-
ment phases.169 Studies of risk factors inform the
development of high performing risk prediction
models, which are subsequently externally validated
in various relevant population subgroups and settings.
Finally, evidence of their effectiveness and impact es-
tablishes them in routine clinical practice. This
scoping review highlights important gaps in evidence
in this regard. No studies exist that have established
the effectiveness of an externally validated risk predic-
tion model, while few extant risk prediction model
development studies for delirium occurrence and
reversibility were identified. Future research agenda
filling this research gap could use existing administra-
tive databases to develop and validate rigorous risk
prediction models; their clinical effectiveness could
be established in subsequent studies. The degree to
which existing databases can be examined might be
compromised due to uncertainty regarding the valid-
ity of the coding for the diagnosis of delirium; vali-
dating the relevant diagnostic codes might therefore
be a prerequisite step.170
In terms of the various study outcomes associated
with delirium management, and the recognized eco-
nomic cost associated with delirium in other settings,
we were unable to find any studies that reported an
economic cost associated with delirium and its man-
agement in PC settings. Although delirium has a re-
ported reversibility of 50% for episodes in an acute
PC unit100, and vigorous pursuit of reversal is often
appropriate, it is also the case in clinical practice
that delirium reversal is often inappropriately pursued
with potentially burdensome and expensive investiga-
tions in the absence of externally validated predictive
models or risk scores to guide the most appropriate
level of therapeutic intervention. There is therefore
a need to link an economic evaluation of delirium
management with the intensity of the therapeutic at-
tempts at delirium reversal. Some researchers have
already begun to work toward developing a commoncore set of predefined delirium outcomes, albeit that
some outcomes will be setting specific.171 Future pri-
mary studies will require broad collaborative input
with substantive interdisciplinary involvement, and
for larger adequately powered trials, multicenter
collaboration is essential. Furthermore, mixed-
methods approaches that capture the experiences of
patients and families and engage knowledge-users to
inform and define the most meaningful outcomes in
rigorously designed controlled trials and other studies
would be well suited to address the complexity of
delirium and its management in the PC setting.172Conclusion
In examining the scope and nature of the published
scientific literature that addresses the assessment,
management, outcomes, and impact of delirium in
PC settings, primary studies are required to address
many existing gaps: lack of external validation of
delirium risk prediction models; lack of reports on
the comparative effectiveness and harms of prevention
strategies and psychomotor classification of delirium;
no data on the degree of variability in delirium man-
agement and related outcomes across the various
types of PC settings, advanced directive and substitute
decision-maker input, the experiential impact of tran-
sition of care location in relation to delirium manage-
ment; and lack of external validation of predictive
models in estimating delirium reversibility. Based on
the number of studies, it appears feasible to conduct
systematic reviews in relation to some aspects: the
epidemiological burden (incidence and prevalence)
of delirium, the risk factors for and diagnosis of
delirium, the test performance of delirium psychomo-
tor classification strategies, the pharmacological and
nonpharmacological management of delirium, and
the prediction of delirium reversibility. The scoping
review’s broad appraisal of study quality and limited
external validity of some studies, based on population
selection, together raised some preliminary concerns
that warrant a more in-depth analysis and also reflect
the importance of rigor in future studies. In addition,
future studies will require broad collaboration from a
multicenter, interdisciplinary, and administrative
knowledge user perspective. Mixed-methods ap-
proaches incorporating experiential outcomes for pa-
tient, family, and professional caregivers will be
required to address some of the more complex aspects
of delirium.
This scoping review’s findings will hopefully guide
researchers and assist us toward the long-term goal
of studies in the SUNDIPS research program: to
generate knowledge synthesis and translation, inform
guidelines and policy for delirium management and
thus improve the experience of patients (and their
676 Vol. 57 No. 3 March 2019Lawlor et al.families) with or at risk of delirium in PC settings and
across the spectrum of end-of-life care.Disclosures and Acknowledgments
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Medline
1. Delirium/
2. deliri*.tw.
3. (acute adj1 confusion*).tw.
4. (acute adj1 brain adj1 syndrome).tw.
5. (metabolic adj1 encephalopath*).tw.
6. (acute adj1 organic adj1 psychosyndrome).tw.
7. (acute adj1 psycho-organic adj1 syndrome).tw.
8. (clouded adj1 state).tw.
9. (clouding adj3 consciousness).tw.
10. (exogenous adj1 psychos*).tw.
11. (toxic adj1 confusion).tw.
12. (toxic adj1 psychos*).tw.
13. Confusion/
14. (acute adj1 confusional adj1 state).tw.
15. (acute adj1 brain adj1 failure).tw.
16. (terminal* adj1 restless*).tw.
17. (terminal adj1 agitation).tw.
18. (psychomotor adj1 agitation).tw.
19. (cognitive adj1 failure).tw.
20. disorientation.tw.
21. (terminal adj2 delir*).tw.
22. encephalopath*.tw.
23. (organic adj3 psychos*).tw.
24. or/1e23
25. Palliative Care/
26. (end* adj3 life).tw.
27. (last year of life or LYOL).tw.
28. palliat*.tw.
29. Terminally Ill/
30. hospice*.tw.
31. (terminal* adj3 (car* or ill* or diseas*)).tw.
32. (terminal-stage* or terminal stage* or dying or (close adj4 death)).tw.
Supplementary Table 1
Database Search Strategies
Database Initial Searcha First Updated Searchb Second Updated Searchc Total
Medline 1904 259 165 2328
Embase 2624 518 339 3481
PsycINFO 494 63 33 590
CINAHL 126 152 123 401
Total 5148 992 660 6800
aJuly 2, 2015.
bDecember 31, 2016.
cMay 16, 2018.
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33. exp Terminal Care/
34. Hospice Care/
35. (dying adj3 care).tw.
36. ((end-stage* or end stage* or incurable or advanced) adj5 (disease* or ill* or care or cancer* or
malignan*)).tw.
37. or/25-36
38. 24 and 37
Embase
1. *delirium/
2. deliri*.tw.
3. (acute adj1 confusion*).tw.
4. (acute adj1 brain adj1 syndrome).tw.
5. (metabolic adj1 encephalopath*).tw.
6. (acute adj1 organic adj1 psychosyndrome).tw.
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8. (clouded adj1 state).tw.
9. (clouding adj3 consciousness).tw.
10. (exogenous adj1 psychos*).tw.
11. (toxic adj1 confusion).tw.
12. (toxic adj1 psychos*).tw.
13. *confusion/
14. (acute adj1 confusional adj1 state).tw.
15. (acute adj1 brain adj1 failure).tw.
16. (terminal* adj1 restless*).tw.
17. (terminal adj1 agitation).tw.
18. (psychomotor adj1 agitation).tw.
19. (cognitive adj1 failure).tw.
20. disorientation.tw.
21. (terminal adj2 delir*).tw.
22. encephalopath*.tw.
23. (organic adj3 psychos*).tw.
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25. exp palliative therapy/
26. (end* adj3 life).tw.
27. (last year of life or LYOL).tw.
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S1 (MH "Confusionþ")
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Supplementary Table 2
General Characteristics of Individual Included Studies (N ¼ 140)
Author Country Palliative Indicator Diagnosis Care Setting Sample Size Study Design Characteristics
Agar et al.40 Australia All or $90% with cancer diagnosis Inpatient PCUs 126 One group NRT or cohorta [P]
Agar et al.41 Australia Mix of life-threatening diagnoses Mix of 11 inpatient hospice and hospital
units
247 RCT
Akechi et al.42 Japan All or $90% with cancer diagnosis Referrals to a psychiatry service in a
cancer center
1721 One group NRT or cohort [R]
Barahona et al.43 Spain All or $90% with cancer diagnosis Hospice (n ¼ 40) and hospital (n ¼ 27) 67 Cross-sectionala [P]
Barnes et al.44 U.K. Mix of life-threatening diagnoses Inpatient PCU in a hospital 120 Before-after study [M]
Boettger et al.45 U.S. All or $90% with cancer diagnosis Psychiatry service in a cancer center 21 One group NRT or cohort [SA]
Boettger et al.46 U.S. All or $90% with cancer diagnosis Psychiatry service in a cancer center 64 Two or multiple groups in NRT
or cohort [SA]
Boettger et al.47 U.S. All or $90% with cancer diagnosis Psychiatry service in a cancer center 42 Two or multiple groups in NRT
or cohort [SA]
Boettger et al.48 U.S. All or $90% with cancer diagnosis Psychiatry service in a cancer center 84 Multiple groups in NRT [SA]
Boettger et al.49 U.S. All or $90% with cancer diagnosis Inpatients in a cancer center 111 Two or multiple groups in NRT
or cohort [SA]
Bond50 U.S. All or $90% with cancer diagnosis Hospitalized older patients with a cancer
diagnosis
76 One group NRT or cohort [SA]
Bond and Neelon51 U.S. All or $90% with cancer diagnosis Hospitalized older adults with a cancer
diagnosis
43 One group NRT or cohort [SA]
Bond et al.52 U.S. All or $90% with cancer diagnosis Hospitalized older patients with a cancer
diagnosis
76 One group NRT or cohort [SA]
Breitbart et al.53 U.S. All or $90% with cancer diagnosis Psychiatry service referrals in a cancer
center
111 One group NRT or cohort [SA]
Breitbart et al.54 U.S. All or $90% with AIDS Referrals to a hospital psychiatry service 244 RCT
Breitbart et al.55 U.S. All or $90% with cancer diagnosis Psychiatry inpatient referrals in a cancer
center
33e51 Cross-sectional [P]
Breitbart et al.56 U.S. All or $90% with cancer diagnosis Psychiatry service in a cancer center 79 One group NRT or cohort [P]
Bruera et al.57 U.S. All or $90% with cancer diagnosis Inpatient PCU in a hospice 129 RCT
Calvo et al.58 Spain Unclear or not reported Inpatient PCU in a hospital 192 One group NRT or cohorta [R]
Candy et al.59 U.S. All or $90% with AIDS Hospital psychiatry consultation service 30 Systematic review
Cerfolio60 U.S. All or $90% with cancer diagnosis Psychiatry referrals from gynecologic
oncology
82 Cross-sectional [P]
Chung et al.61 Italy All or $90% with cancer diagnosis Inpatient PCUs 393 One group NRT or cohort [P]
De and Wand62 Multiple Mix of life-threatening diagnoses Hospital inpatients 19e906 Systematic review
de la Cruz et al.63 U.S. All or $90% with cancer diagnosis Hospital inpatient PC consult team 771 One group NRT or cohort [R]
de la Cruz et al.64 U.S. All or $90% with cancer diagnosis Community PC service 78 One group NRT or cohort [R]
de la Cruz et al.65 U.S. All or $90% with cancer diagnosis Inpatient PCU in a cancer center 556 Cross-sectional [R]
de la Cruz et al.66 U.S. All or $90% with cancer diagnosis Inpatient PCU in a cancer center 329 Two or multiple groups in NRT
or cohort [SA]
Detroyer et al.67 Netherlands Unclear or not reported Inpatient PCU in a hospital 48 One group NRT or cohort [P]
Doriath et al.68 Belgium All or $90% with cancer diagnosis Inpatient unit in a cancer center 100 One group NRT or cohort [P]
Elsayem et al.69 U.S. All or $90% with cancer diagnosis Inpatient PCU in a hospital 25 One group NRT or cohort [P]
Elsayem et al.70 U.S. All or $90% with cancer diagnosis Emergency department in a cancer
center
243 Cross-sectional [P]
Fadul et al.71 U.S. Solid tumors; hematological
malignancies
Hospital inpatient PC consult team 250 Two or multiple groups in NRT
or cohort [R]
Fang et al.72 Taiwan All or $90% with cancer diagnosis Inpatient PCU in a hospice 228 One group NRT or cohort [P]
Fann et al.73 U.S. All or $90% with cancer diagnosis Pre- and post-hematopoietic stem cell
transplant
90 One group NRT or cohort [P]
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Felton et al.74 U.S. Unclear or not reported Inpatient PCU in a hospital 319 Two or multiple groups in NRT
or cohorta [R]
Fernandez et al.75 U.S. All or $90% with AIDS Referrals to a psychiatry consultation
service
206 One group NRT or cohort [P]
Freeman et al.76 Canada Mix of life-threatening diagnoses Community PC service 6769 Cross-sectional [R]
Gagnon et al.77 Canada All or $90% with cancer diagnosis Hospice and PCU in hospital 1516 Two or multiple groups in NRT
or cohort [P]
Gagnon et al.78 Canada All or $90% with cancer diagnosis Inpatient PCU in a hospice 89 One group NRT or cohort [P]
Gagnon et al.79 Canada All or $90% with cancer diagnosis Inpatient PCU in a hospice 200 Cross-sectionala [R]
Gaudreau et al.80 Canada All or $90% with cancer diagnosis Hospital oncology/internal medicine
unit
134 One group NRT or cohort [SA]
Gaudreau et al.81 Canada All or $90% with cancer diagnosis Hospital hemato-oncology internal
medicine unit
261 One group NRT or cohort [P]
Gaudreau et al.82 Canada Unclear or not reported Hospital hemato-oncology internal
medicine unit
146 One group NRT or cohort [P]
Gaudreau et al.83 Canada All or $90% with cancer diagnosis Hospital hemato-oncology internal
medicine unit
114 One group NRT or cohort [P]
Godfrey et al.84 Ireland Unclear or not reported Inpatient PCU in a hospice 40 One group NRT or cohort [P]
Gonc¸alves et al.85 Portugal All or $90% with cancer diagnosis Inpatient PCU in a cancer center 135 One group NRT or cohort [P]
Gonc¸alves et al.86 Portugal All or $90% with cancer diagnosis Inpatient PCU in a cancer center 79 Two or multiple groups in NRT
or cohort [P]
Gonc¸alves et al.87 Portugal All or $90% with cancer diagnosis Inpatient PCU in a cancer center 300 One group NRT or cohort [P]
Gulcin et al.88 Turkey All or $90% with cancer diagnosis Inpatient PCU in a hospital 213 One group NRT or cohort [P]
Hey et al.89 U.K. Unclear or not reported Hospital inpatient PC consult team 292 Before-after studya [M]
Hjermstad et al.90 Norway All or $90% with cancer diagnosis Multiple palliative care settings; 22 in
total
20e393 Systematic review
Hosie et al.91 Multiple All or $90% with cancer diagnosis Inpatient PCUs in hospice and hospital
settings
1079 Systematic review
Hosie et al.92 Australia All or $90% with cancer diagnosis Inpatient PCU in a hospital 47 Cross-sectional [P]
Hui et al.93 U.S. and Brazil All or $90% with cancer diagnosis Inpatient PCU in a cancer center 352 One group NRT or cohort [P]
Hui et al.94 U.S. All or $90% with cancer diagnosis Inpatient PCU in a cancer center 90 RCT
Keeley95 Multiple Mix of life-threatening diagnoses Systematic review (multiple settings) 30e42 Systematic review
Kim et al.96 South Korea All or $90% with cancer diagnosis Inpatient PCU in a hospital 322 One group NRT or cohort [P]
Kishi et al.97 Japan All or $90% with cancer diagnosis Psychiatry service referrals in an acute
care hospital
29 One group NRT or cohort [P]
Lam et al.98 Hong Kong All or $90% with cancer diagnosis Inpatient PCU in a hospital 28 One group NRT or cohort [P]
Landa Teran et al.99 Spain All or $90% with cancer diagnosis Inpatient PCU in a hospital 1826 Cross-sectionala [U]
Lawlor et al.100 Canada All or $90% with cancer diagnosis Inpatient PCU in a hospital 104 One group NRT or cohort [P]
Lawlor et al.101 Canada All or $90% with cancer diagnosis Inpatient PCU in a hospital 104 Cross-sectional [P]
Leonard et al.102 Ireland 87.2% had a cancer diagnosis Inpatient PCU in a hospice 121 One group NRT or cohort [P]
Lin et al.103 Taiwan All or $90% with cancer diagnosis Inpatient PCU in a hospital 30 RCT
Livermore and Xavier104 U.S. All or $90% with cancer diagnosis Outpatient PC clinic 52 One group NRT or cohorta [R]
Ljubisavljevic and Kelly105 Australia All or $90% with cancer diagnosis Inpatient oncology ward 113 One group NRT or cohort [P]
Massie et al.106 U.S. All or $90% with cancer diagnosis Psychiatric assessment in hospital
oncology unit
19 One group NRT or cohort [P]
Matsuo et al.107 Japan All or $90% with cancer diagnosis Multiple: mix of inpatient hospice and
hospital inpatient PC team referrals
207 One group NRT or cohort [P]
Matsuoka et al.108 Japan All or $90% with cancer diagnosis Inpatient PCU in a hospital 166 One group NRT or cohort [R]
Meagher et al.109 Multiple Unclear or not reported Subgroup of hospice inpatients
(n ¼ 249)
487 Cross-sectional [R]
Meagher et al.110 Multiple Unclear or not reported Inpatient PCU in a hospice 269 Case control [R]
Metitieri et al.111 Italy All or $90% with cancer diagnosis Inpatient PCU in a hospital 60 One group NRT or cohort [U]
Minagawa et al.112 Japan All or $90% with cancer diagnosis Inpatient PCU in a hospital 93 One group NRT or cohort [P]
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Author Country Palliative Indicator Diagnosis Care Setting Sample Size Study Design Characteristics
Miyajima et al.113 Japan All or $90% with cancer diagnosis Hospital inpatient PC consult team 255 Cross-sectional [P]
Mizukami et al.114 Japan All or $90% with cancer diagnosis Inpatient PCU in a hospital 56 Cross-sectionala [P]
Mizukami et al.115 Japan All or $90% with cancer diagnosis Inpatient PCU in a hospital 76 One group NRT or cohorta [R]
Moreira et al.116 Portugal All or $90% with cancer diagnosis Hospital inpatient PC consult team 119 One group NRT or cohorta [P]
Morita et al.117 Japan All or $90% with cancer diagnosis Inpatient PCU in a hospital 21 One group NRT or cohort [P]
Morita et al.118 Japan All or $90% with cancer diagnosis Inpatient PCU in a hospital 237 One group NRT or cohort [P]
Neefjes et al.119 Netherlands Mix of life-threatening diagnoses Medical oncology unit in a hospital 574 One group NRT or cohorta [R]
Nowels et al.120 U.S. Mix of life-threatening diagnoses Hospice research network (inpatient and
community)
299 Cross-sectional [P]
Oligario et al.121 U.S. Dementia Inpatient PCU in a hospice 50 One group NRT or cohort [P]
Olofsson et al.122 U.S. All or $90% with cancer diagnosis Psychiatry consult service in a cancer
center
90 One group NRT or cohort [R]
O’Sullivan et al.123 Ireland Unclear or not reported Inpatient PCU in a hospice 77 One group NRT or cohort [P]
Perrar et al.124 Germany Mix of life-threatening diagnoses Three studies included; AIDS (n ¼ 1)
and cancer (n ¼ 2)
30e121 Systematic review
Plaschke et al.125 Germany All or $90% with cancer diagnosis Inpatient PCU in a hospital 100 One group NRT or cohort [P]
Porteous et al.126 U.K. Unclear or not reported Inpatient PCU in a hospice 298 One group NRT or cohort [P]
Rainsford et al.127 Australia All or $90% with cancer diagnosis Inpatient PCU in a hospice 51 Cross-sectional [P]
Rao et al.128 U.S. Mix of life-threatening diagnoses Inpatient PCU in a hospice 22 One group NRT or cohort [P]
Ryan et al.129 Ireland All or $90% with cancer diagnosis Inpatient PCU in a hospice 85 One group NRT or cohort [P]
Sagawa et al.130 Japan All or $90% with cancer diagnosis Referrals to a hospital psychiatry service 100 One group NRT or cohort [P]
Sanchez-Roman et al.131 Mexico All or $90% with cancer diagnosis Multiple settings based on search word,
‘‘palliative.’’
34e1516 Systematic review
Sands et al.132 Australia All or $90% with cancer diagnosis Inpatient PC referrals in an oncology
center
21 Cross-sectional [P]
Shin et al.133 U.S. All or $90% with cancer diagnosis Inpatient PCU in a cancer center 167 One group NRT or cohort [P]
Slatore et al.134 U.S. Mix of life-threatening diagnoses Community PC service 105 One group NRT or cohort [SA]
Spiller and Keen135 U.K. All or $90% with cancer diagnosis Inpatient PCU in a hospice 100 Mixed cross-sectional and one
group NRT or cohort [P]
Stillman and Rybicki136 U.S. 79% had a cancer diagnosis Inpatient PCU in a hospital 31 Cross-sectional [P]
Tanaka et al.137 Japan All or $90% with cancer diagnosis Cancer center 114 Two or multiple groups in NRT
or cohort [R]
Tatematsu et al.138 Japan All or $90% with cancer diagnosis Hospital inpatient PC consult team 48 One group NRT or cohort [R]
Trzepacz et al.139 U.S. Hepatic failure Hospital psychiatry referrals from a
medical service
40 Cross-sectional [P]
Uchida et al.140 Japan All or $90% with cancer diagnosis General medical ward (hospital) 61 One group NRT or cohort [P]
Uldall and Berghuis141 U.S. All or $90% with AIDS Hospice type setting for AIDS patients 137 One group NRT or cohort [R]
Zimmerman et al.142 U.S. Unclear or not reported Hospital inpatient PC consult team 217 Case control [R]
Zuriarrain Reyna et al.143 Spain Unclear or not reported Inpatient PCU in a hospital 55 One group NRT or cohorta [P]
PC ¼ palliative care; PCU ¼ palliative care unit; NRT ¼ nonrandomized trial; RCT ¼ randomized controlled trial.
aConference abstract only; [P] ¼ prospective; [R] ¼ retrospective; [M] ¼ mixed prospective and retrospective; [SA] ¼ secondary analysis of prospective study data; [U] ¼ unclear as to whether prospective or
retrospective.
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Supplementary Table 3
Delirium Diagnostic Criteria and Validated Assessment Tools Used in Included Studiesa
Reference
Number ICD-109 DSM-III144 DSM-IIIR145
DSM-IV146 or
DSM-IV-TR147 DSM-58 CAM12
DRS148 or
DRS-98-R149 MDAS55 Other Comment
40 X
41 X X
42 X
43 X
44 X
45 X X
46 X X
47 X X
48 X X
49 X
50 X NEECHAM150
51 X NEECHAM
52 X NEECHAM
53 X X
54 X X
55 X X
56 X X
57 X
58 X
59 X X SR
60 X
61 X
62 X X X X X X Psychiatrist interview; SR
63 X X
64 X
65 X X
66 X X
67 X X DOS67
68 X
69 X
70 X X
71 X
72 X
73 X X
74 X
75 X
76 X InterRAI-PC151
77 X CRS152
78 X
79 X NuDESC82
80 X
81 X Nu-DESC > 2
82 X X X
83 X Nu-DESC > 1
84 X X X
85 X
86 X
87 X
(Continued)
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Supplementary Table 3
Continued
Reference
Number ICD-109 DSM-III144 DSM-IIIR145
DSM-IV146 or
DSM-IV-TR147 DSM-58 CAM12
DRS148 or
DRS-98-R149 MDAS55 Other Comment
88 X X
89 X
90 X X X X X SR
91 X X X X X X X Psychiatrist interview; SR
92 X X X Nu-DESC
93 X
94 X
95 X X Psychiatrist interview; SR
96 X X X
97 X X
98 X
99 X
100 X
101 X X
102 X X X
103 X
104 X FAM-CAM153
105 X
106 X
107 X
108 X
109 X X X
110 X
111 X
112 X
113 X
114 X
115 X
116 X
117 X
118 X
119 X DOS
120 X
121 X
122 X Psychiatrist interview
123 X
124 X X X Nu-DESC; SR
125
126 X
127 X X
128 X
129 X X X X X CTD154, SOMCT155
130 X
131 X Standard criteria or validated
instruments; SR
132 X X X
133 X
134 X
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135 X
136 X
137 X ICDSC156
138 X
139 X
140 X X
141 X
142 X Validated chart audit tool
143 X
ICD-10 ¼ International Classification of Disease, 10th edition;9 DSM-III ¼ Diagnostic Statistical Manual of Mental Disorders, third edition144; DSM-III-R ¼ Diagnostic Statistical Manual of Mental Disorders, third edition
revised145; DSM-IV ¼ Diagnostic Statistical Manual of Mental Disorders, fourth edition146; DSM-IV-TR ¼ Diagnostic Statistical Manual of Mental Disorders, fourth edition, text revised147; DSM-5 ¼ Diagnostic Statistical
Manual of Mental Disorders, fifth edition8; CAM ¼ Confusion Assessment Method12; DRS ¼ Delirium Rating Scale148; DRS-98-R ¼ Delirium Rating Scale (Revised-98 version)149; MDAS ¼ Memorial Delirium Assessment
Scale55; NEECHAM ¼ NEECHAM Confusion Scale150; SR ¼ multiple diagnostic tools as part of either formal systematic reviews59,62,90,91,95 or systematic literature review studies124,131; InterRAI-PC ¼ Residential Assess-
ment InstrumentePalliative Care version151; CRS ¼ Confusion Rating Scale152; Nu-DESC ¼ Nursing Delirium Screening Scale82; FAM-CAM ¼ Confusion Assessment Method (Family Version)153; DOS ¼ Delirium Obser-
vation Scale67; CTD ¼ Cognitive Test of Delirium154; SOMCT ¼ Short Orientation Memory Concentration Test155; ICDSC ¼ Intensive Care Delirium Screening Checklist.156
aGuide to initials used (in order of appearance in table).
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Supplementary Table 4
Studies of Comparative Effectiveness or Harms Outcomes
Comparative Approach
Study
Reference
Number Specific Comparisona Study Outcomesb
Direct comparison of two
or more active study
interventions
46 Haloperidol versus risperidone C, M
47 Aripiprazole versus haloperidol C, M
48 Haloperidol, aripiprazole, olanzapine, risperidone C, M
54 Haloperidol, chlorpromazine, and lorazepam C, M
59 Haloperidol versus chlorpromazine versus
lorazepam; overlaps with primary study54
C, M
62 Systematic review comparing multiple screening
tools for delirium
O [most effective screening tool
for population/settings]
74 Haloperidol versus nonhaloperidol antipsychotics
(olanzapine, risperidone, quetiapine)
M, O [length of stay; sedation
level; QTc prolongation]
80 Nu-DESC versus CRS O [delirium detection; cost-
effectiveness description]
86 Haloperidol alone versus haloperidol and
midazolam
O [agitation; consciousness]
94 Haloperidol þ lorazepam versus
haloperidol þ placebo
C, D, F, I, M, O [change on
agitation-sedation scale;
communication capacity;
discharged alive]
95 Systematic review with one included study
comparing haloperidol versus chlorpromazine vs
lorazepam, overlaps with primary study54
C, M
103 Haloperidol versus olanzapine C, M
124 Systematic literature review study: haloperidol
versus aripiprazole; chlorpromazine versus
haloperidol versus lorazepam
C, M
Comparison of one or more
active study interventions
(test or treatment) versus
placebo/no intervention/
reference standard
41 Risperidone versus haloperidol versus placebo C, D, M
57 Normal saline 1 L per day versus placebo using
MDAS and Nu-DESC as measures of delirium
severity and RASS as a measure of agitation-
sedation
C, D, J, O [change in delirium
severity scores; change in
agitation-sedation using RASS]
62 Systematic review comparing multiple screening
tools for delirium
O [most effective screening tool
for population/settings]
72 DRS-Chinese version versus routine care O [detection of delirium]
77 Multicomponent prevention strategies versus
routine care
A, C, L, O [adherence to or
completion of screening;
patient-days in delirium;
duration of delirium episode;
time to onset of incident
delirium]
95 Systematic review included a study of hydration with
hypodermoclysis versus standard care
C, M
101 MDAS versus MMSE versus DSM-IV criteria H
113 Psychiatrist assessment versus nurse assessment O [delirium recognition]
121 Subjective nurse ratings versus objective researcher
ratings using the CAM
O [recognition of delirium
occurring in patients with
dementia]
122 Haloperidol versus no antipsychotic M
127 Screening versus routine clinical assessment A, O [comparative rates of
recognition of delirium or
subsyndromal delirium]
131 Systematic literature review study of delirium in
adult patients receiving palliative care; included
exercise study138
A, C, K, O [multiple outcomes of
included studies as part of
systematic review]
138 Exercise therapy versus nonexercise therapy O [antipsychotic doses used as a
severity index of delirium]
Single-arm, pre- and
post-intervention
comparison
44 CAM versus routine care H, O [delirium documentation
(as an index of recognition);
acceptability of screening to
health care staff; delirium
prevalence]
45 Aripiprazole C, M
53 Antipsychotic use (haloperidol, risperidone,
olanzapine, aripiprazole)
B, C, O [functional status change]
56 Olanzapine C, M
69 Olanzapine in patients who already were on
haloperidol
C, M
(Continued)
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Supplementary Table 4
Continued
Comparative Approach
Study
Reference
Number Specific Comparisona Study Outcomesb
75 Haloperidol and lorazepam B, C, D, M
85 Haloperidol and midazolam combination M, O [time to control of agitation]
89 CAM screening O [prevalence of documented
delirium]
97 Risperidone B, C, M
107 Initiation of corticosteroid treatment A, O [severity of psychomotor
disturbance]
117 Opioid switch to fentanyl B, C, I, O [functional status
change]
124 Systematic literature review study that included a
study of olanzapine56
C
126 CAM H, O [acceptability and utility of
screening procedure]
128 CAM screening H, O [burden of regular screening
for staff and patients]
133 Response to haloperidol C, D, M, O [need to switch to a
different antipsychotic]
Nu-DESC ¼ Nursing Delirium Screening Scale82; CRS ¼ Confusion Rating Scale152; MDAS ¼ Memorial Delirium Assessment Scale55; RASS ¼ Richmond
Agitation-Sedation Scale157; DRS-Chinese version ¼ Chinese version of the Delirium Rating Scale158; MMSE ¼ MinieMental State Examination159; DSM-IV ¼
Diagnostic and Statistical Manual of Mental Disorders, fourth edition146; CAM ¼ Confusion Assessment Method.12
aGuide to initials used in third column (specific comparison) in order of appearance.
bCoded study outcomes: A, new onset delirium; B, delirium reversal or nonreversal; C, delirium severity change other than reversal or nonreversal; D, death/sur-
vival; E, falls; F, length of inpatient stay; G, cost or incremental cost-effectiveness ratio; H, inconvenience/burden as defined by authors; I, proxy caregiver ratings
of patient distress due to other symptoms; J, quality of life; K, family distress (as defined by authors); L, adverse events related to screening, diagnostic testing, risk
prediction; M, adverse events related to therapy; N, palliative sedation required to control delirium; O, other outcomes.
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